Ulrich Dauer
Directeur/Bestuurslid bij Atriva Therapeutics GmbH
Vermogen: 26 719 $ op 30-04-2024
Actieve functies van Ulrich Dauer
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Directeur/Bestuurslid | - | - |
Loopbaan van Ulrich Dauer
Eerdere bekende functies van Ulrich Dauer
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
VIVORYON THERAPEUTICS N.V. | Directeur/Bestuurslid | - | 14-08-2023 |
Algemeen Directeur | 01-05-2018 | 14-08-2023 | |
Financieel Directeur/CFO | 01-05-2018 | 01-04-2021 | |
4SC AG | Algemeen Directeur | 01-01-1997 | 31-03-2013 |
Oprichter | 01-01-1997 | 31-03-2013 | |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Algemeen Directeur | 24-05-2017 | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Algemeen Directeur | - | - |
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Corporate Officer/Principal | 01-11-2013 | - |
Opleiding van Ulrich Dauer
Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Statistieken
Internationaal
Duitsland | 8 |
Operationeel
Chief Executive Officer | 4 |
Director/Board Member | 2 |
Founder | 1 |
Sectoraal
Health Technology | 7 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
4SC AG | Health Technology |
VIVORYON THERAPEUTICS N.V. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Health Technology |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
- Beurs
- Insiders
- Ulrich Dauer
- Ervaring